10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-CXCR3 / GPR9 / CD183 Reference Antibody (Genzyme patent anti-CXCR3)

Recombinant Antibody
Catalog # APR10043

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P49682
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	40660


Additional Information

Target/Specificity	CXCR3 / GPR9 / CD183
Endotoxin Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	CXCR3
Synonyms	GPR9
Function	[Isoform 1]: Receptor for the C-X-C chemokines CXCL9, CXCL10 and CXCL11, and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G- protein signaling pathway (PubMed:12782716). Probably promotes cell chemotaxis response. Upon activation by PF4, induces activated T- lymphocyte migration mediated via downstream Ras/extracellular signal- regulated kinase (ERK) signaling. [Isoform 3]: Mediates the activity of CXCL11.
Cellular Location	[Isoform 1]: Cell membrane; Multi-pass membrane protein
Tissue Location	Isoform 1 and isoform 2 are mainly expressed in heart, kidney, liver and skeletal muscle. Isoform 1 is also expressed in placenta. Isoform 2 is expressed in endothelial cells. Expressed in T-cells (at protein level).


Images



Anti-CXCR3 / GPR9 / CD183 Reference Antibody (Genzyme patent anti-CXCR3) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-CXCR3 / GPR9 / CD183 Reference Antibody (Genzyme patent anti-CXCR3) is 100%, determined by SEC-HPLC.



Immobilized human CXCR3 VLP Protein at 8 ug/mL can bind Genzyme patent anti-CXCR3, EC50=0.173 ug/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.